MCID: SCL009
MIFTS: 48

Sclerosing Cholangitis

Categories: Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Sclerosing Cholangitis

MalaCards integrated aliases for Sclerosing Cholangitis:

Name: Sclerosing Cholangitis 12 74 58 15 17
Primary Sclerosing Cholangitis 71
Cholangitis, Sclerosing 71
Fibrosing Cholangitis 12

Classifications:

Orphanet: 58  
Rare hepatic diseases


External Ids:

Disease Ontology 12 DOID:14268
MeSH 44 D015209
SNOMED-CT 67 4032000
ICD10 32 K83.09
UMLS via Orphanet 72 C0008313
Orphanet 58 ORPHA447771
UMLS 71 C0008313 C0566602

Summaries for Sclerosing Cholangitis

MalaCards based summary : Sclerosing Cholangitis, also known as primary sclerosing cholangitis, is related to sclerosing cholangitis, neonatal and ulcerative colitis, and has symptoms including icterus An important gene associated with Sclerosing Cholangitis is CLDN1 (Claudin 1), and among its related pathways/superpathways are Tuberculosis and Cell adhesion molecules. The drugs Simvastatin and Ursodeoxycholic acid have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and colon, and related phenotypes are digestive/alimentary and liver/biliary system

Wikipedia : 74 Primary sclerosing cholangitis (PSC) is a long-term progressive disease of the liver and gallbladder... more...

Related Diseases for Sclerosing Cholangitis

Diseases in the Sclerosing Cholangitis family:

Cholangitis, Primary Sclerosing Secondary Sclerosing Cholangitis

Diseases related to Sclerosing Cholangitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 683)
# Related Disease Score Top Affiliating Genes
1 sclerosing cholangitis, neonatal 33.3 DCDC2 CLDN1
2 ulcerative colitis 32.1 TNF TLR4 PRTN3 NOD2 HLA-DRB1
3 colitis 31.9 TNF TLR4 NOD2 MADCAM1 HLA-DRB1
4 autoimmune pancreatitis 31.8 TNF TLR4 HLA-DRB1 CFTR ALB
5 autoimmune hepatitis 31.6 TNF HLA-DRB1 GPT F2 ALB
6 pouchitis 31.5 TNF TLR4 NOD2
7 liver cirrhosis 31.5 TNF TLR4 HLA-DRB1 GPT F2 ALB
8 cholangitis, primary sclerosing 31.5 TNF PRTN3 NR1I2 NR1H4 NOD2 MIR222
9 pericholangitis 31.3 ABCB4 ABCB11
10 crohn's disease 31.3 TNF TLR4 NOD2 MADCAM1 HLA-DRB1 FUT2
11 ileitis 31.3 TNF TLR4 NOD2 MADCAM1
12 acquired immunodeficiency syndrome 31.1 TNF MADCAM1 HLA-B ALB
13 cholestasis 31.1 NR1I2 NR1H4 GPT GPBAR1 F2 ALB
14 obstructive jaundice 31.1 TNF TLR4 GPT GPBAR1 F2 ALB
15 choledocholithiasis 31.0 GPT F2 ALB ABCB4
16 acute pancreatitis 31.0 TNF TLR4 GPT CFTR
17 acute cholangitis 31.0 GPT F2 ALB
18 spondylitis 31.0 TNF NOD2 HLA-B
19 esophageal varix 31.0 GPT F2 ALB
20 portal hypertension 30.9 TNF TLR4 NR1H4 GPT F2 CFTR
21 cholecystitis 30.9 TLR4 GPT F2 ALB ABCB4
22 graft-versus-host disease 30.9 TNF HLA-DRB1 HLA-B
23 liver disease 30.9 TNF NR1I2 NR1H4 GPT F2 ALB
24 ascending cholangitis 30.8 MADCAM1 GPT F2 ALB
25 diarrhea 30.8 TNF TLR4 NOD2 GPT CFTR ALB
26 primary biliary cholangitis 30.8 PRTN3 NR1I2 NR1H4 HLA-DRB1 GPT GPBAR1
27 echinococcosis 30.8 TNF TLR4 HLA-DRB1 HLA-B
28 hepatic coma 30.8 GPT F2 ALB
29 autoimmune hepatitis type 1 30.8 HLA-DRB1 GPT
30 cholelithiasis 30.7 NR1H4 GPT ALB ABCB4
31 bile duct cysts 30.7 GPT ALB ABCB4 ABCB11
32 klatskin's tumor 30.7 GPT F2 ALB
33 autoimmune gastritis 30.7 TNF HLA-DRB1 HLA-B
34 acalculous cholecystitis 30.7 GPT F2 ALB ABCB4
35 suppurative cholangitis 30.7 GPT ABCB4
36 bacterial infectious disease 30.7 TNF TLR4 NOD2 CFTR
37 bilirubin metabolic disorder 30.7 GPT F2 ALB ABCB4 ABCB11
38 hepatic encephalopathy 30.6 TNF GPT F2 ALB
39 celiac disease 1 30.6 TNF TLR4 NOD2 HLA-DRB1 HLA-B GPT
40 inflammatory bowel disease 30.6 TNF TLR4 PRTN3 NR1I2 NR1H4 NOD2
41 spondyloarthropathy 1 30.6 TNF TLR4 PRTN3 NOD2 HLA-B
42 viral hepatitis 30.6 TNF TLR4 HLA-DRB1 GPT F2 ALB
43 pleural empyema 30.5 GPT F2 ALB
44 acute liver failure 30.5 GPT F2 ALB
45 hepatitis a 30.5 TNF TLR4 GPT F2 ALB
46 proteasome-associated autoinflammatory syndrome 1 30.5 TNF TLR4 ALB
47 red cell aplasia 30.5 HLA-DRB1 HLA-B ALB
48 pure red-cell aplasia 30.5 HLA-DRB1 HLA-B ALB
49 ileus 30.4 TNF F2 CFTR
50 alopecia areata 30.4 TNF HLA-DRB1 HLA-B

Graphical network of the top 20 diseases related to Sclerosing Cholangitis:



Diseases related to Sclerosing Cholangitis

Symptoms & Phenotypes for Sclerosing Cholangitis

UMLS symptoms related to Sclerosing Cholangitis:


icterus

MGI Mouse Phenotypes related to Sclerosing Cholangitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.61 ABCB4 ALB CFTR F2 FUT2 NOD2
2 liver/biliary system MP:0005370 9.28 ABCB11 ABCB4 ALB CFTR GPBAR1 NR1H4

Drugs & Therapeutics for Sclerosing Cholangitis

Drugs for Sclerosing Cholangitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 3 79902-63-9 54454
2
Ursodeoxycholic acid Approved, Investigational Phase 3 128-13-2 31401
3
Bezafibrate Approved, Investigational Phase 3 41859-67-0 39042
4 Lipid Regulating Agents Phase 3
5 Hypolipidemic Agents Phase 3
6 Antimetabolites Phase 3
7 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
8 Anticholesteremic Agents Phase 3
9 Clofibric Acid Phase 3 882-09-7
10
Cladribine Approved, Investigational Phase 2 4291-63-8 20279
11
Curcumin Approved, Experimental, Investigational Phase 1, Phase 2 458-37-7 969516
12
Sulfasalazine Approved Phase 2 599-79-1 5353980 5359476
13
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
14
Fenofibrate Approved Phase 1, Phase 2 49562-28-9 3339
15
Tretinoin Approved, Investigational, Nutraceutical Phase 2 302-79-4 5538 444795
16 Volixibat Experimental, Investigational Phase 2 1025216-57-2
17 Mitomycins Phase 2
18 Alkylating Agents Phase 2
19 Anti-Inflammatory Agents Phase 1, Phase 2
20 Hormones Phase 2
21 2-chloro-3'-deoxyadenosine Phase 2
22 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
23 Antirheumatic Agents Phase 1, Phase 2
24 Anti-HIV Agents Phase 2
25 Antiviral Agents Phase 2
26 TAK-652 Phase 2
27 Anti-Retroviral Agents Phase 2
28 Antibodies, Monoclonal Phase 2
29 Calcium, Dietary Phase 2
30 Liver Extracts Phase 2
31 Bile Acids and Salts Phase 2
32 Streptococcal polysaccharide type III group B Phase 2
33 Analgesics, Non-Narcotic Phase 2
34 Analgesics Phase 2
35 Interleukin-2 Phase 2
36 Immunosuppressive Agents Phase 2
37 Immunologic Factors Phase 2
38 Angiogenesis Inhibitors Phase 2
39 Keratolytic Agents Phase 2
40 Dermatologic Agents Phase 2
41
Calcium Nutraceutical Phase 2 7440-70-2 271
42
Budesonide Approved Phase 1 51333-22-3 63006 5281004
43
Vancomycin Approved Phase 1 1404-90-6 441141 14969
44
Minocycline Approved, Investigational Phase 1 10118-90-8 5281021
45
Rifaximin Approved, Investigational Phase 1 80621-81-4 6436173 46783403
46
Lenalidomide Approved Phase 1 191732-72-6 216326
47
rituximab Approved Phase 1 174722-31-7 10201696
48 Anti-Asthmatic Agents Phase 1
49 Respiratory System Agents Phase 1
50 Hormone Antagonists Phase 1

Interventional clinical trials:

(show top 50) (show all 100)
# Name Status NCT ID Phase Drugs
1 Evaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis. Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
2 Multicenter Randomized Trial Comparing Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Unknown status NCT01398917 Phase 3
3 Probiotics in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease- a Randomized Placebo-Controlled Cross-Over Trial Unknown status NCT00161148 Phase 3 Probiotics
4 The Effect of Bezafibrate on Cholestatic Itch Unknown status NCT02701166 Phase 3 Bezafibrate;Placebo
5 Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects Completed NCT01802073 Phase 3 Oral Vancomycin
6 Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis Completed NCT00059202 Phase 2, Phase 3 Ursodeoxycholic Acid
7 Digital SpyGlass Cholangioscopy Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy Completed NCT02967926 Phase 3
8 Effect of Simvastatin on the Prognosis of Primary Sclerosing Cholangitis (PSC); A Randomized, Double-blind, Placebo Controlled Multicenter Study Recruiting NCT04133792 Phase 3 Simvastatin 40mg;Placebo oral tablet
9 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis Recruiting NCT03890120 Phase 3 Cilofexor;Placebo
10 Double-blind, Randomized, Placebo-controlled, Phase III Study Comparing norUrsodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis Recruiting NCT03872921 Phase 3 norUrsodeoxycholic Acid
11 A Prospective, Randomized, Multi-centered, Placebo-controlled Clinical Trial of Oral Vanycomycin in Adults With Primary Sclerosing Cholangitis Recruiting NCT03710122 Phase 2, Phase 3 Vancomycin
12 Double Blind, Multicentric, Randomized, Placebo-controlled Trial, Evaluating the Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy Not yet recruiting NCT04309773 Phase 3 Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy;Placebo of Bezafibrate in addition to standard UDCA therapy
13 A Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease Withdrawn NCT03035058 Phase 3 Vedolizumab;Placebo
14 Phase 2 Study of Mitomycin C Therapy for Biliary Strictures in Patients With Primary Sclerosing Cholangitis Unknown status NCT01688024 Phase 2 Mitomycin C;Normal saline
15 Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis Completed NCT00004762 Phase 2 cladribine
16 A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis Completed NCT02704364 Phase 2
17 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Primary Sclerosing Cholangitis Completed NCT02177136 Phase 2 OCA;Placebo
18 A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Sclerosing Cholangitis Completed NCT02061540 Phase 2 LUM001
19 Double-blind,Randomized, Placebo-controlled, Phase II Dose-finding Study Comparing Different Doses of Norursodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis Completed NCT01755507 Phase 2 norUDCA;Placebo
20 PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT02653625 Phase 2 Cenicriviroc 150 mg
21 A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT01672853 Phase 2
22 Investigation of the Activity of Vidofludimus Calcium, a Novel, Orally Available, Small Molecule Inhibitor of Dihydroorotate Dehydrogenase, as a Treatment for Primary Sclerosing Cholangitis (PSC) Completed NCT03722576 Phase 2 Vidofludimus calcium
23 A Single Arm, Two-stage, Multi-centre, Phase II Clinical Trial Investigating the Safety and Activity of the Use of BTT1023 Targeting Vascular Adhesion Protein (VAP-1), in the Treatment of Patients With Primary Sclerosing Cholangitis (PSC). Completed NCT02239211 Phase 2 BTT1023
24 An Open-Label Pilot Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis Completed NCT02978339 Phase 1, Phase 2 Curcumin
25 A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis Completed NCT02943460 Phase 2 Cilofexor;Placebo to match Cilofexor
26 A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT03333928 Phase 2 HTD1801;Placebo
27 Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis. Completed NCT02424175 Phase 1, Phase 2
28 A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC) Recruiting NCT03561584 Phase 2 Sulfasalazine;Placebo
29 A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis Recruiting NCT04663308 Phase 2 Volixibat;Placebo
30 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating The Safety And Efficacy Of CM-101 In Subjects With Primary Sclerosing Cholangitis- The SPRING Study Recruiting NCT04595825 Phase 2
31 A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC) Recruiting NCT04480840 Phase 2 PLN-74809;Placebo
32 An Adaptive,Multicentre, Phase IIa, Multi-disease Trial Investigating the Safety & Activity of a Single Infusion of Selected Mesenchymal Stromal Cells in the Treatment of Patients With Primary Sclerosing Cholangitis & Autoimmune Hepatitis Recruiting NCT02997878 Phase 1, Phase 2
33 Intra-arterial Injection of Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis Active, not recruiting NCT03516006 Phase 1, Phase 2 UCMSC;UDCA
34 Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach Active, not recruiting NCT01988506 Phase 2 Interleukin 2
35 A Phase 2, Randomized, Double-Blind Study of HTD1801 vs Ursodeoxycholic Acid (UDCA) in Adolescents With Primary Sclerosing Cholangitis (PSC) Not yet recruiting NCT03678480 Phase 2 HTD1801;Ursodeoxycholic Acid
36 A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC) Suspended NCT04024813 Phase 2 Seladelpar;Placebo to match Seladelpar
37 Pilot Study of Fenofibrate in Primary Sclerosing Cholangitis Terminated NCT01142323 Phase 1, Phase 2 fenofibrate
38 Open Label, Phase II Investigation of Thalidomide for the Treatment of Primary Sclerosing Cholangitis Terminated NCT00953615 Phase 2 Thalidomide
39 A Randomized, Open-label, Phase 2 Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC) Terminated NCT03394781 Phase 2 DUR-928
40 An Efficacy Trial of Low Dose All-trans Retinoic Acid (ATRA) in Patients With Primary Sclerosing Cholangitis Terminated NCT03359174 Phase 2 All-trans retinoic acid
41 Primary Sclerosing Cholangitis: Value of Computerized Tomographic Cholangiography and Intraductal Volumetric Measurement in Determining the Prognosis Withdrawn NCT00588458 Phase 2
42 Pilot Study of Budesonide for Patients With Primary Sclerosing Cholangitis Completed NCT00004842 Phase 1 budesonide
43 A First in Human, Randomized, Double-Blind Study to Assess Safety, Tolerability, and Pharmacokinetics of Single, Ascending Doses of HTD1801 in Healthy Subjects Completed NCT03099603 Phase 1 HTD1801
44 Evaluation of Docosahexaenoic Acid (DHA) for the Treatment of Primary Sclerosing Cholangitis (PSC) Completed NCT00325013 Phase 1 Docosahexaenoic Acid (DHA)
45 A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis Completed NCT01085760 Phase 1 Vancomycin;Vancomycin;Metronidazole;Metronidazole;Vancomycin
46 Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: A Pilot Withdrawal/Reinstitution Trial Completed NCT01088607 Phase 1 ursodeoxycholic acid (UDCA)
47 The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin. Completed NCT01322386 Phase 1 Vancomycin
48 Open Label Pilot Study Evaluating Minocycline in Patients With Primary Sclerosing Cholangitis (PSC) Completed NCT00630942 Phase 1 Minocycline
49 A Pilot Study of Xifaxan in Patients With Primary Sclerosing Cholangitis Completed NCT01695174 Phase 1 Xifaxan
50 An Open Label Pilot Trial of Erlotinib (Tarceva) in Primary Sclerosing Cholangitis With Trisomy 7 Completed NCT00955149 Phase 1 Erlotinib (Tarceva)

Search NIH Clinical Center for Sclerosing Cholangitis

Genetic Tests for Sclerosing Cholangitis

Anatomical Context for Sclerosing Cholangitis

MalaCards organs/tissues related to Sclerosing Cholangitis:

40
Liver, T Cells, Colon, Neutrophil, Pancreas, Spleen, Kidney

Publications for Sclerosing Cholangitis

Articles related to Sclerosing Cholangitis:

(show top 50) (show all 6311)
# Title Authors PMID Year
1
Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. 61
32531342 2021
2
Cerebral Vascular Thrombosis Associated With Ulcerative Colitis and Primary Sclerosing Cholangitis. 61
32773435 2021
3
Trends in Incidence of Autoimmune Liver Diseases and Increasing Incidence of Autoimmune Hepatitis. 61
32526342 2021
4
Hepatic NFAT signaling regulates the expression of inflammatory cytokines in cholestasis. 61
33039404 2021
5
Eligibility for Liver Transplantation in Patients with Perihilar Cholangiocarcinoma. 61
32901308 2021
6
Primary Sclerosing Cholangitis-Associated Pouchitis: A Distinct Clinical Phenotype. 61
33549866 2021
7
Management of primary sclerosing cholangitis and its complications: an algorithmic approach. 61
33377990 2021
8
Systematic Review and Meta-Analysis of Outcomes after Ileal Pouch-Anal Anastomosis in Primary Sclerosing Cholangitis-Ulcerative Colitis. 61
33544128 2021
9
The role of oral vancomycin in inducing remission for biologic-experienced ulcerative colitis with concomitant primary sclerosing cholangitis and liver transplantation. 61
33130984 2021
10
[Surgical treatment of primary sclerosing cholangitis : Experiences from 30 years in a single center cohort with 173 consecutive patients]. 61
32488382 2021
11
Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis. 61
33474546 2021
12
Exome Sequencing in Patient-Parent Trios Suggests New Candidate Genes for Early-onset Primary Sclerosing Cholangitis. 61
33590606 2021
13
Impact of inflammatory bowel disease and azathioprine on long-term outcomes after liver transplantation for primary sclerosing cholangitis. 61
33569894 2021
14
Associations of neopterin and kynurenine-tryptophan ratio with survival in primary sclerosing cholangitis. 61
33583308 2021
15
Systematic review: non-invasive prognostic tests for primary sclerosing cholangitis. 61
33608929 2021
16
Alterations of the salivary and fecal microbiome in patients with primary sclerosing cholangitis. 61
32949377 2021
17
A Patient with Primary Sclerosing Cholangitis and Diffuse Biliary Dilation. 61
32598888 2021
18
Overexpression of Cancer-Associated Stem Cell Gene OLFM4 in the Colonic Epithelium of Patients With Primary Sclerosing Cholangitis. 61
33570127 2021
19
Clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2020 (Revision of the clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2012). 61
33586343 2021
20
A case with life-threatening secondary sclerosing cholangitis caused by nivolumab. 61
33200345 2021
21
Autoimmune Hepatitis: Predictors of Native Liver Survival in Children and Adolescents. 61
33500120 2021
22
False-positive PET/CT finding of hepatic inflammatory pseudotumor in IgG4-related sclerosing cholangitis. 61
33582317 2021
23
Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. 61
32282399 2021
24
Gut Microbiome: A Potential Modifiable Risk Factor in Biliary Atresia. 61
33427793 2021
25
A case of juvenile eosinophilic cholangitis: Rapid peripheral blood hypereosinophilia after admission leading to diagnosis. 61
33553674 2021
26
Discriminant equation using mucosally expressed cytokines and transcription factor for making definite diagnosis of inflammatory bowel disease unclassified. 61
33593285 2021
27
Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease. 61
33225252 2021
28
Difficulty in differentiating between IgG4-related hepatic inflammatory pseudotumor and intrahepatic cholangiocarcinoma. 61
33037585 2021
29
Treatment and outcome of ulcerative colitis during the first 10 years after diagnosis in a prospectively followed population-based cohort. 61
33577739 2021
30
Prednisolone-responsive primary sclerosing cholangitis with autoimmune hemolytic anemia: a case report and review of the literature. 61
33038000 2021
31
Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial. 61
33031833 2021
32
De novo Colorectal and Pancreatic Cancer in Liver Transplant Recipients: Identifying the Higher Risk Populations. 61
33544906 2021
33
Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis. 61
33159471 2021
34
Editorial: serologic antibodies in primary sclerosing cholangitis-a tell-tale sign of compromised gut-liver immunity? Authors' reply. 61
33368503 2021
35
Acquired factor V inhibitor: Success of steroids in a patient with primary sclerosing cholangitis, ulcero haemorragic rectocolitis, biological Biermer's disease. 61
33516887 2021
36
Antineutrophil cytoplasmic antibody profiles differ according to type of primary sclerosing cholangitis and autoimmune hepatitis. 61
33567045 2021
37
Disease-Specific Waitlist Outcomes in Liver Transplantation. 61
33423330 2021
38
Liver Transplantation for Langerhans Cell Histiocytosis: A U.S. Population-Based Analysis and Systematic Review of the Literature. 61
33484600 2021
39
Oral Vancomycin or Ursodeoxycholic acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials. 61
33403699 2021
40
Guideline review: British Society of Gastroenterology/UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. 61
33456743 2021
41
Effectiveness of Ursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis with Ulcerative Colitis: A Pediatric Case. 61
33551380 2021
42
Letter to the Editor: Imaging monitoring of primary sclerosing cholangitis patients. 61
33427311 2021
43
Manganese and copper levels in patients with primary biliary cirrhosis and primary sclerosing cholangitis. 61
33428478 2021
44
Editorial: serologic antibodies in primary sclerosing cholangitis - a tell-tale sign of compromised gut-liver immunity? 61
33368511 2021
45
Immunosuppressant treatment for IgG4-related sclerosing cholangitis: A case report. 61
33511195 2021
46
Presentation and Outcomes of Autoimmune Hepatitis Type 1 and Type 2 in Children: A Single-center Study. 61
32796427 2021
47
Predicting Outcomes in Pediatric Ulcerative Colitis for Management Optimization: Systematic Review and Consensus Statements From the Pediatric Inflammatory Bowel Disease-Ahead Program. 61
32976826 2021
48
Antigen presentation, autoantibody production, and therapeutic targets in autoimmune liver disease. 61
33110250 2021
49
Liver transplant recipients have an increased risk of developing colorectal adenomas: Results from a retrospective study. 61
33190329 2021
50
NAFLD exacerbates cholangitis and promotes cholangiocellular carcinoma in mice. 61
33506599 2021

Variations for Sclerosing Cholangitis

Expression for Sclerosing Cholangitis

Search GEO for disease gene expression data for Sclerosing Cholangitis.

Pathways for Sclerosing Cholangitis

GO Terms for Sclerosing Cholangitis

Cellular components related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.13 TNF TLR4 PRTN3 NOD2 MADCAM1 HLA-DRB1
2 extracellular exosome GO:0070062 9.91 PRTN3 HLA-DRB1 HLA-B GPT FUT2 F2
3 integral component of plasma membrane GO:0005887 9.56 TNF TLR4 HLA-DRB1 HLA-B CLDN1 CFTR
4 recycling endosome membrane GO:0055038 9.54 HLA-B CFTR ABCB11
5 cell surface GO:0009986 9.17 TNF TLR4 NOD2 HLA-DRB1 HLA-B CFTR
6 intercellular canaliculus GO:0046581 9.16 ABCB4 ABCB11

Biological processes related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.97 TNF TLR4 MADCAM1 HLA-DRB1 HLA-B
2 defense response to bacterium GO:0042742 9.88 TNF TLR4 NR1H4 NOD2
3 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.78 TNF TLR4 NOD2 HLA-DRB1
4 positive regulation of interleukin-6 production GO:0032755 9.77 TNF TLR4 NOD2
5 positive regulation of JNK cascade GO:0046330 9.75 TNF TLR4 NOD2
6 negative regulation of tumor necrosis factor production GO:0032720 9.71 TLR4 NR1H4 NOD2
7 cellular response to lipopolysaccharide GO:0071222 9.71 TNF TLR4 NR1H4 NOD2
8 negative regulation of interleukin-6 production GO:0032715 9.7 TNF TLR4 NR1H4
9 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.69 TNF TLR4 NOD2
10 positive regulation of interleukin-8 production GO:0032757 9.67 TNF TLR4 NOD2
11 positive regulation of interleukin-1 beta production GO:0032731 9.63 TNF TLR4 NOD2
12 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.56 TNF TLR4
13 T-helper 1 type immune response GO:0042088 9.55 TLR4 HLA-DRB1
14 positive regulation of insulin secretion involved in cellular response to glucose stimulus GO:0035774 9.54 NR1H4 HLA-DRB1 CFTR
15 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.5 TNF TLR4 NOD2
16 negative regulation of interferon-gamma production GO:0032689 9.46 TLR4 NR1H4 NOD2 HLA-DRB1
17 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.43 TNF NOD2
18 detection of bacterium GO:0016045 9.43 NOD2 HLA-DRB1 HLA-B
19 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.43 TNF TLR4 NOD2 MIR222 HLA-DRB1 GPBAR1
20 cellular response to bile acid GO:1903413 8.8 NR1H4 GPBAR1 ABCB4

Molecular functions related to Sclerosing Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATPase activity, coupled to transmembrane movement of substances GO:0042626 9.13 CFTR ABCB4 ABCB11
2 bile acid receptor activity GO:0038181 8.62 NR1H4 GPBAR1

Sources for Sclerosing Cholangitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....